The present Glioblastoma multiforme (GBM) market has several unmet needs. Poor prognosis, 10-15 months median survival rate, no curative treatment to the patients, limited treatment options, drug resistance, incapability of therapies to cross BBB (blood-brain-barrier), intratumor heterogeneity, and a high mortality rate are among them.
The cardinal approach is always surgery followed by radiation therapy with chemotherapy BiCNU (carmustine), Avastin (bevacizumab), and Temodar (temozolomide) as an adjunct. Further, no standard of care is available in the market for recurrent GBM market.
However, over the turn of the decade, with advances in medical sc...
